Related Experiment Video

Updated: Aug 10, 2026

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
07:46

Assessing Endothelial Vasodilator Function with the Endo-PAT 2000

Published on: October 16, 2010

Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced

B L Lopez1, T A Christopher, T L Yue

  • 1Department of Surgery, Jefferson Medical College, Thomas Jefferson University Hospital, Philadelphia, PA 19107-5004, USA.

Pharmacology
|September 1, 1995
PubMed

Insights

Carvedilol protects rat aorta rings from free radical damage and endothelial dysfunction. This antihypertensive drug scavenges free radicals, preserving vascular function and nitric oxide effects.

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Oxidative Stress Biology

Background:

  • Endothelial cell (EC) dysfunction is a key factor in cardiovascular disease.
  • Free radicals, such as superoxide, contribute to EC dysfunction and vasoconstriction.
  • Carvedilol is an antihypertensive drug with known antioxidant properties.

Purpose of the Study:

  • To evaluate carvedilol's ability to protect rat aorta rings from free-radical-induced EC dysfunction.
  • To investigate the mechanisms underlying carvedilol's protective effects, including free radical scavenging and nitric oxide (NO) potentiation.

Main Methods:

  • Rat aorta rings were exposed to pyrogallol, a superoxide generator.
  • Vascular function was assessed by measuring acetylcholine (ACh)-induced vasorelaxation in intact rings.
  • Function of EC-denuded rings was assessed by measuring S-nitroso-N-acetylpenicillamine (SNAP)-induced vasorelaxation.
  • Carvedilol's effects were compared to vehicle and propanolol (a pure beta-receptor antagonist).

Main Results:

  • Carvedilol significantly reduced pyrogallol-induced vasoconstriction compared to vehicle.
  • Carvedilol significantly protected against pyrogallol-induced EC dysfunction, enhancing ACh-induced vasorelaxation.
  • These protective effects were not observed with propanolol.
  • Carvedilol preserved SNAP-induced vasorelaxation in EC-denuded rings, suggesting direct antioxidant activity.

Conclusions:

  • Carvedilol protects vascular function from free radical-induced damage.
  • Carvedilol's protective mechanisms involve scavenging free radicals and enhancing nitric oxide bioavailability.
  • These findings support carvedilol's potential therapeutic role in conditions involving oxidative stress and endothelial dysfunction.

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart09:38

Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart

Published on: May 19, 2017

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...